

# CPSI Scientists Present at ISBiotech 2017

**Dr. John M. Baust gives presentation focused on new cryopreservation technologies designed to improve cell recovery at scientific conference held in Washington DC**

March 8, 2017

OWEGO, NY -- CPSI Biotech's CEO and Lead Scientist gave a podium presentation Monday morning at the 2017 ISBiotech 7<sup>th</sup> Annual Spring Meeting in Washington, DC (March 6-8). The presentation titled "New Technologies for Improved Handling of Cryopreserved Samples", given by Dr. John M. Baust, focused on the recent research and development activities relating to CPSI's *SmartThaw*<sup>TM</sup> dry thawing device and RevitalICE cell culture reagent.

As part of the presentation, Dr. Baust focused on educating and reviewing attendees' current cryopreservation practices and the challenges associated with many of protocols, as well as discussing new technologies and development efforts in the area of modulating the cellular-molecular response to cryopreservation as a path to improve cell recovery and function. Dr. Baust also presented data recently collected by CPSI scientists related to thawing of samples cryopreserved in 5 ml cryovials using *SmartThaw*<sup>TM</sup>, a next generation device developed by CPSI Biotech for controlled and rapid dry thawing.

In his presentation, Dr. Baust highlighted studies using *SmartThaw*<sup>TM</sup> with CHO, 786-O, human endothelial and smooth muscle cells. Providing insight into the data presented, Dr. Baust stated "*SmartThaw*<sup>TM</sup> is designed to provide a viable alternative to water baths offering a clean, dry and documentable process while delivering equivalent or better cell recovery. The data presented illustrated the improved processing and outcome (including improved cell recovery) delivered by *SmartThaw*<sup>TM</sup> compared to traditional water bath thawing. These benefits are achieved in cell samples frozen in various volumes and storage containers (vials, 25, 250 and 500 ml freeze bags)."

Discussions also focused on the importance of the molecular response of cells to the freeze/thaw process and its impact on downstream sample quality. On this subject Baust stated, "while the impact of molecular response on cryopreservation outcome has been known for several years now, translation of this knowledge has been limited. Importantly, while strategies have been developed to better freeze cells and control these responses, these approaches do little to aid in the recovery of previously frozen samples. In order to increase the utility of previously banked samples, we are now working on strategies to improve the post thaw cell culture process, thereby reducing the level of cell loss and improving overall sample quality."

*SmartThaw*<sup>TM</sup> is targeted for commercial launch in 2017. When asked about the upcoming launch, Dr. Kristi Snyder (Director of Operations at CPSI) stated "Reception of the final system design and the pending launch has been highly positive. As cryopreservation is an enabling tool for many research and clinical areas, the demand for devices and processes to improve handling and distribution continues to grow. We believe that *SmartThaw*<sup>TM</sup> will provide a vital link in

improving handling of cryopreserved cell products. As such, it is our belief that *SmartThaw™* has tremendous potential and will have a significant impact on the industry.”

The ISBiotech conference was organized by the International Society for Bioprocess Technology, an organization dedicated to scientists and engineers with the day to day responsibility of managing and creating scalable and reproducible processes. The society organizes networking events, conferences and web-based resources for professionals in the biotech industry to access for learning, educating, and sharing resources, information and techniques that help improve medical products.

About CPSI Biotech - CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

*Disclosure Notice: The information contained in this release is as of March 8, 2017. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".*

*With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defensible, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI's ability to raise the capital that is required to accomplish the foregoing.*

**Contact**

John M Baust, Ph.D., President & Lead Scientist

Kristi Snyder, Ph.D., Director of Operations

**Email:** [contact@cpsibiotech.com](mailto:contact@cpsibiotech.com)

**Web:** [www.cpsibiotech.com](http://www.cpsibiotech.com)